| Name | Title | Contact Details |
|---|
MED e-care Healthcare Solutions Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Novocardia is on a mission to transform how cardiovascular disease care is delivered in the United States, and aims to help patients with heart and vascular disease live longer, healthier, and more satisfying lives. We are committed to putting cardiologists, and their patients, at the center of care by investing in our partner practices, deploying purpose-built data and analytics tools to improve patient outcomes, and enabling our partners to transition more successfully to value-based care.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
RoundGlass is committed to enabling individuals to live their Journey of holistic Wellbeing and Meaningful Living™. The RoundGlass community of associates, portfolio companies, fellows, partners and ambassadors advocate and develop solutions across the RoundGlass holistic Wellbeing Pillars. The RoundGlass Wholistic Wellbeing Pillars: 1. Live – Wellbeing of self: From the right health care decision to celebrating life 2. Learn – Wellbeing of the future: Living with purpose and mastering key qualities 3. Give – Wellbeing of society: Empowering community wellbeing so that all members live with dignity 4. Sustain – Wellbeing of the planet: Meaningful programs that improve the environment
Pure Power Athletics, Inc. d/b/a Makkar Athletics Group is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.